MARAVAI LIFESCIENCES HOLDINGS, INC. - 10-Q Filing

Maravai Lifesciences reports Q3 2026 results and details implementation of the A2025 Corporate Realignment Plan.

SEC EDGAR ·

Tickers: $MRVI

Read the full article at SEC EDGAR

More Regulatory news